Oncoinvent ASA (KLDVK) - Net Assets
Based on the latest financial reports, Oncoinvent ASA (KLDVK) has net assets worth Nkr277.49 Million NOK (≈ $29.20 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr507.79 Million ≈ $53.43 Million USD) and total liabilities (Nkr230.30 Million ≈ $24.23 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Oncoinvent ASA to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr277.49 Million |
| % of Total Assets | 54.65% |
| Annual Growth Rate | 25.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.46 |
Oncoinvent ASA - Net Assets Trend (2021–2025)
This chart illustrates how Oncoinvent ASA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Oncoinvent ASA worth.
Annual Net Assets for Oncoinvent ASA (2021–2025)
The table below shows the annual net assets of Oncoinvent ASA from 2021 to 2025. Also explore KLDVK net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr277.49 Million ≈ $29.20 Million |
+3.63% |
| 2024-12-31 | Nkr267.76 Million ≈ $28.18 Million |
-5.62% |
| 2023-12-31 | Nkr283.70 Million ≈ $29.85 Million |
+47.75% |
| 2022-12-31 | Nkr192.02 Million ≈ $20.21 Million |
+71.03% |
| 2021-12-31 | Nkr112.27 Million ≈ $11.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oncoinvent ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Nkr277.49 Million | 100.00% |
| Total Equity | Nkr277.49 Million | 100.00% |
Oncoinvent ASA Competitors by Market Cap
The table below lists competitors of Oncoinvent ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZUARI INDUSTRIES LIMITED
NSE:ZUARIIND
|
$90.31 Million |
|
Samil Pharm
KO:000520
|
$90.35 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
$90.36 Million |
|
Globe International Ltd
AU:GLB
|
$90.36 Million |
|
Antalpha Platform Holding Co
NASDAQ:ANTA
|
$90.29 Million |
|
Barington/Hilco Acquisition
NASDAQ:BHAC
|
$90.28 Million |
|
DHI Group Inc
NYSE:DHX
|
$90.26 Million |
|
Pylon Public Company Limited
BK:PYLON
|
$90.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncoinvent ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 267,760,000 to 277,488,000, a change of 9,728,000 (3.6%).
- Net loss of 48,103,000 reduced equity.
- New share issuances of 46,628,000 increased equity.
- Other factors increased equity by 11,203,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-48.10 Million | -17.34% |
| Share Issuances | Nkr46.63 Million | +16.8% |
| Other Changes | Nkr11.20 Million | +4.04% |
| Total Change | Nkr- | 3.63% |
Book Value vs Market Value Analysis
This analysis compares Oncoinvent ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.49x to 3.09x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | Nkr2.05 | Nkr5.10 | x |
| 2022-12-31 | Nkr2.10 | Nkr5.10 | x |
| 2023-12-31 | Nkr2.32 | Nkr5.10 | x |
| 2024-12-31 | Nkr2.19 | Nkr5.10 | x |
| 2025-12-31 | Nkr1.65 | Nkr5.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncoinvent ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.85%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.83x
- Recent ROE (-17.34%) is below the historical average (-5.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.78% | 6.18% | 0.19x | 1.53x | Nkr-9.23 Million |
| 2022 | -2.62% | -8.89% | 0.18x | 1.62x | Nkr-24.24 Million |
| 2023 | 2.01% | 19.18% | 0.07x | 1.51x | Nkr-22.67 Million |
| 2024 | -11.43% | -29.96% | 0.21x | 1.80x | Nkr-57.39 Million |
| 2025 | -17.34% | -42.85% | 0.22x | 1.83x | Nkr-75.85 Million |
Industry Comparison
This section compares Oncoinvent ASA's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $931,500,031
- Average return on equity (ROE) among peers: -62.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncoinvent ASA (KLDVK) | Nkr277.49 Million | 1.78% | 0.83x | $90.30 Million |
| African Agriculture Holdings Inc. (AAGR) | $-13.80 Million | 0.00% | 0.00x | $4.98 |
| Archer-Daniels-Midland Company (ADM) | $5.05 Billion | 9.59% | 0.73x | $33.40 Billion |
| Forafric Global PLC Ordinary Shares (AFRI) | $5.32 Million | -457.58% | 45.29x | $297.41 Million |
| Adecoagro SA (AGRO) | $1.03 Billion | 0.92% | 0.73x | $1.36 Billion |
| Agroz Inc. Ordinary Shares (AGRZ) | $163.20K | -177.61% | 22.30x | $4.79 Million |
| Alico Inc (ALCO) | $165.37 Million | -5.72% | 1.53x | $309.56 Million |
| AquaBounty Technologies Inc (AQB) | $191.92 Million | -11.54% | 0.11x | $4.84 Million |
| Bunge Limited (BG) | $1.20 Billion | -0.42% | 2.85x | $22.97 Billion |
| Cal-Maine Foods Inc (CALM) | $66.08 Million | 18.48% | 2.56x | $3.50 Billion |
| Del Monte Corporation (DMC) | $1.63 Billion | 3.81% | 0.54x | $1.45 Billion |
About Oncoinvent ASA
Kaldvik AS engages in the salmon farming business in Iceland. It also operates smolt stations. The company was incorporated in 2020 and is headquartered in Eskifjörður, Iceland. Kaldvik AS was formerly known as Ice Fish Farm AS and changed its name to Kaldvik AS in August 2024. Kaldvik AS operates as a subsidiary of Austur Holding As.